SELLAS Life Sciences (NASDAQ: SLS) is a development-stage biopharmaceutical company with its focus on novel cancer immunotherapies for a wide array of cancer indications. The company’s lead product candidate, galinpepimut-S (GPS), is a cancer immunotherapeutic agent that targets Wilms Tumor 1 (WT1) protein, which is present in various tumor types. The product has potential as a monotherapy or in combination to address a broad spectrum of hematologic cancers and solid tumor indications. SELLAS recently received Orphan Drug designations from the U.S. Food & Drug Administration and the European Medicines Agency for GPS in acute myeloid leukemia (AML) and malignant pleural mesothelioma (MPM). GPS additionally received FDA Fast Track designation for AML and MPM. For more information, visit the company’s website at www.sellaslifesciences.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
